Neoplastic disease after liver transplantation: Focus on de novo neoplasms

World Journal of Gastroenterology

Volumn 21, Issue 29, 2015, Pages 8811-8816

  Burra, Patrizia ^a   Rodriguez Castro, Kryssia ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

De novo neoplasms; Hepatocellular carcinoma; Immunosuppression; Liver transplantation; MTOR inhibitors

Indexed keywords

CALCINEURIN INHIBITOR; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; IMMUNOSUPPRESSIVE AGENT;

BREAST CANCER; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; COLORECTAL CANCER; DE NOVO NEOPLASM; DONOR; ESOPHAGUS CANCER; FEMALE GENITAL TRACT CANCER; GRAFT RECIPIENT; HEAD AND NECK CANCER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG CANCER; LYMPHOPROLIFERATIVE DISEASE; NEOPLASM; OPEN STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN CANCER; STOMACH CANCER; SYSTEMATIC REVIEW (TOPIC); UROGENITAL TRACT CANCER; ADVERSE EFFECTS; DONOR SELECTION; IMMUNOCOMPROMISED PATIENT; MORTALITY; NEOPLASMS; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

DONOR SELECTION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TISSUE DONORS; TREATMENT OUTCOME;

EID: 84939839536     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i29.8753     Document Type: Review

References (184)

1. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Sanchez W, Gores GJ. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology 2009; 137: 2010-2017 [PMID: 19766646 DOI: 10.1053/j.gastro.2009.08.070]
2. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010; 10: 1420-1427 [PMID: 20486907 DOI: 10.1111/ j.1600-6143.2010.03126.x]
3. Chandok N, Watt KD. Burden of de novo malignancy in the liver transplant recipient. Liver Transpl 2012; 18: 1277-1289 [PMID:22887956 DOI: 10.1002/lt.23531]
4. Sanchez W, Talwalkar JA, Gores GJ. "Will all liver transplantation patients eventually die from cancer?". J Hepatol 2006; 44: 13-18 [PMID: 16297490 DOI: 10.1016/j.jhep.2005.10.007]
5. Jain AB, Yee LD, Nalesnik MA, Youk A, Marsh G, Reyes J, Zak M, Rakela J, Irish W, Fung JJ. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 1998; 66: 1193-1200 [PMID: 9825817]
6. Haagsma EB, Hagens VE, Schaapveld M, van den Berg AP, de Vries EG, Klompmaker IJ, Slooff MJ, Jansen PL. Increased cancer risk after liver transplantation: a population-based study. J Hepatol 2001; 34: 84-91 [PMID: 11211912]
7. Baccarani U, Adani GL, Serraino D, Lorenzin D, Gambato M, Buda A, Zanus G, Vitale A, Piselli P, De Paoli A, Bresadola V, Risaliti A, Toniutto P, Cillo U, Bresadola F, Burra P. De novo tumors are a major cause of late mortality after orthotopic liver transplantation. Transplant Proc 2009; 41: 1303-1305 [PMID: 19460546 DOI: 10.1016/j.transproceed.2009.03.079]
8. Verran DJ, Mulhearn MH, Dilworth PJ, Balderson GA, Munn S, Chen JW, Fink MA, Crawford MD, McCaughan GW. Nature and outcomes of the increased incidence of colorectal malignancy after liver transplantation in Australasia. Med J Aust 2013; 199: 610-612 [PMID: 24182227]
9. Schrem H, Kurok M, Kaltenborn A, Vogel A, Walter U, Zachau L, Manns MP, Klempnauer J, Kleine M. Incidence and longterm risk of de novo malignancies after liver transplantation with implications for prevention and detection. Liver Transpl 2013; 19: 1252-1261 [PMID: 24106037 DOI: 10.1002/lt.23722]
10. Belloni-Fortina A, Piaserico S, Bordignon M, Gambato M, Senzolo M, Russo FP, Peserico A, De Matteis G, Perissinotto E, Cillo U, Vitale A, Alaibac M, Burra P. Skin cancer and other cutaneous disorders in liver transplant recipients. Acta Derm Venereol 2012; 92: 411-415 [PMID: 22377797 DOI: 10.2340/00015555-1316]
11. Berg D, Otley CC. Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002; 47: 1-17; quiz 18-20 [PMID: 12077575]
12. Carroll RP, Ramsay HM, Fryer AA, Hawley CM, Nicol DL, Harden PN. Incidence and prediction of nonmelanoma skin cancer post-renal transplantation: a prospective study in Queensland, Australia. Am J Kidney Dis 2003; 41: 676-683 [PMID: 12612993 DOI: 10.1053/ajkd.2003.50130]
13. Otley CC, Cherikh WS, Salasche SJ, McBride MA, Christenson LJ, Kauffman HM. Skin cancer in organ transplant recipients: effect of pretransplant end-organ disease. J Am Acad Dermatol 2005; 53: 783-790 [PMID: 16243126]
14. Mithoefer AB, Supran S, Freeman RB. Risk factors associated with the development of skin cancer after liver transplantation. Liver Transpl 2002; 8: 939-944 [PMID: 12360438 DOI: 10.1053/ jlts.2002.35551]
15. Saigal S, Norris S, Muiesan P, Rela M, Heaton N, O'Grady J. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transpl 2002; 8: 482-487 [PMID: 12004349DOI: 10.1053/jlts.2002.32977]
16. Shroff R, Rees L. The post-transplant lymphoproliferative disorder-a literature review. Pediatr Nephrol 2004; 19: 369-377 [PMID: 14986084 DOI: 10.1007/s00467-003-1392-x]
17. Dierickx D, Tousseyn T, De Wolf-Peeters C, Pirenne J, Verhoef G. Management of posttransplant lymphoproliferative disorders following solid organ transplant: an update. Leuk Lymphoma 2011; 52: 950-961 [PMID: 21338285 DOI: 10.3109/10428194.2011.557453]
18. Aversa SM, Stragliotto S, Marino D, Calabrese F, Rigotti P, Marchini F, Gambino A, Feltrin G, Boso C, Canova F, Soldà C, Mazzarotto R, Burra P. Post-transplant lymphoproliferative disorders after heart or kidney transplantation at a single centre: presentation and response to treatment. Acta Haematol 2008; 120: 36-46 [PMID: 18797163 DOI: 10.1159/000155234]
19. Burra P, Buda A, Livi U, Rigotti P, Zanus G, Calabrese F, Caforio A, Menin C, Canova D, Farinati F, Luciana Aversa SM. Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection? Eur J Gastroenterol Hepatol 2006; 18: 1065-1070 [PMID: 16957512 DOI: 10.1097/01.meg.0000231752.50587.ae]
20. Winkelhorst JT, Brokelman WJ, Tiggeler RG, Wobbes T. Incidence and clinical course of de-novo malignancies in renal allograft recipients. Eur J Surg Oncol 2001; 27: 409-413 [PMID: 11417989 DOI: 10.1053/ejso.2001.1119]
21. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514-1516 [PMID: 7902900]
22. Libertiny G, Watson CJ, Gray DW, Welsh KI, Morris PJ. Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients. Br J Surg 2001; 88: 1330-1334 [PMID: 11578286 DOI: 10.1046/j.0007-1323.2001.01924.x]
23. Angel LF, Cai TH, Sako EY, Levine SM. Posttransplant lymphoproliferative disorders in lung transplant recipients: clinical experience at a single center. Ann Transplant 2000; 5: 26-30 [PMID: 11147026]
24. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905-913 [PMID: 15147424 DOI: 10.1111/j.1600-6143.2004.00450.x]
25. Vincenti F, Larsen CP, Alberu J, Bresnahan B, Garcia VD, Kothari J, Lang P, Urrea EM, Massari P, Mondragon-Ramirez G, Reyes-Acevedo R, Rice K, Rostaing L, Steinberg S, Xing J, Agarwal M, Harler MB, Charpentier B. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012; 12: 210-217 [PMID: 21992533 DOI: 10.1111/j.1600-6143.2011.03785.x]
26. Dantal J, Soulillou JP. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med 2005; 352: 1371-1373 [PMID: 15800234 DOI: 10.1056/NEJMe058018]
27. Benlloch S, Berenguer M, Prieto M, Moreno R, San Juan F, Rayón M, Mir J, Segura A, Berenguer J. De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years? Am J Transplant 2004; 4: 596-604 [PMID: 15023152 DOI: 10.1111/j.1600-6143.2004.00380.x]
28. Duvoux C, Pageaux GP, Vanlemmens C, Roudot-Thoraval F, Vincens-Rolland AL, Hézode C, Gaulard P, Miguet JP, Larrey D, Dhumeaux D, Cherqui D. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation 2002; 74: 1103-1109 [PMID: 12438954 DOI: 10.1097/01.TP.0000031543.16208.1C]
29. McLaughlin K, Wajstaub S, Marotta P, Adams P, Grant DR, Wall WJ, Jevnikar AM, Rizkalla KS. Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C. Liver Transpl 2000; 6: 570-574 [PMID: 10980055 DOI: 10.1053/jlts.2000.7578]
30. Penn I. De novo malignances in pediatric organ transplant recipients. Pediatr Transplant 1998; 2: 56-63 [PMID: 10084762]
31. Smets F, Sokal EM. Epstein-Barr virus-related lymphoproliferation in children after liver transplant: role of immunity, diagnosis, and management. Pediatr Transplant 2002; 6: 280-287 [PMID: 12234267]
32. Cacciarelli TV, Reyes J, Jaffe R, Mazariegos GV, Jain A, Fung JJ, Green M. Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients. Pediatr Transplant 2001; 5: 359-364 [PMID: 11560756]
33. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, Lennette ET, Martinez OM, Krams SM, Berquist WE, So SK, Esquivel CO. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995; 59: 524-529 [PMID: 7533344]
34. Younes BS, McDiarmid SV, Martin MG, Vargas JH, Goss JA, Busuttil RW, Ament ME. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation 2000; 70: 94-99 [PMID: 10919581]
35. Guthery SL, Heubi JE, Bucuvalas JC, Gross TG, Ryckman FC, Alonso MH, Balistreri WF, Hornung RW. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation 2003; 75: 987-993 [PMID: 12698085 DOI: 10.1097/01.TP.0000057244.03192.BD]
36. Fukushima D, Sato K, Kawagishi N, Ohuchi N, Satomi S. Epstein-Barr virus--associated posttransplantation lymphoproliferative disorder with tacrolimus metabolism deterioration in infants after living-donor liver transplantation. Transplantation 2015; 99: 114-119 [PMID: 24846306 DOI: 10.1097/TP.0000000000000255]
37. Narkewicz MR, Green M, Dunn S, Millis M, McDiarmid S, Mazariegos G, Anand R, Yin W. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience. Liver Transpl 2013; 19: 730-740 [PMID: 23696264 DOI: 10.1002/ lt.23659]
38. Khedmat H, Taheri S. Lymphoproliferative disorders in pediatric liver allograft recipients: a review of 212 cases. Hematol Oncol Stem Cell Ther 2012; 5: 84-90 [PMID: 22828371]
39. Gupta S, Fricker FJ, González-Peralta RP, Slayton WB, Schuler PM, Dharnidharka VR. Post-transplant lymphoproliferative disorder in children: recent outcomes and response to dual rituximab/low-dose chemotherapy combination. Pediatr Transplant 2010; 14: 896-902 [PMID: 20642490 DOI: 10.1111/j.1399-3046.2010.01370.x]
40. Smets F, Vajro P, Cornu G, Reding R, Otte JB, Sokal E. Indications and results of chemotherapy in children with posttransplant lymphoproliferative disease after liver transplantation. Transplantation 2000; 69: 982-984 [PMID: 10755561]
41. Euvrard S, Kanitakis J. Skin cancers after liver transplantation: what to do? J Hepatol 2006; 44: 27-32 [PMID: 16290909 DOI: 10.1016/j.jhep.2005.10.010]
42. Berber I, Altaca G, Aydin C, Dural A, Kara VM, Yigit B, Turkmen A, Titiz MI. Kaposi's sarcoma in renal transplant patients: predisposing factors and prognosis. Transplant Proc 2005; 37: 967-968 [PMID: 15848593 DOI: 10.1016/j.transproceed.2004.12.034]
43. Serraino D, Angeletti C, Carrieri MP, Longo B, Piche M, Piselli P, Arbustini E, Burra P, Citterio F, Colombo V, Fuzibet JG, Dal Bello B, Targhetta S, Grasso M, Pozzetto U, Bellelli S, Dorrucci M, Dal Maso L, Busnach G, Pradier C, Rezza G. Kaposi's sarcoma in transplant and HIV-infected patients: an epidemiologic study in Italy and France. Transplantation 2005; 80: 1699-1704 [PMID: 16378064]
44. Piselli P, Busnach G, Citterio F, Frigerio M, Arbustini E, Burra P, Pinna AD, Bresadola V, Ettorre GM, Baccarani U, Buda A, Lauro A, Zanus G, Cimaglia C, Spagnoletti G, Lenardon A, Agozzino M, Gambato M, Zanfi C, Miglioresi L, Di Gioia P, Mei L, Ippolito G, Serraino D. Risk of Kaposi sarcoma after solidorgan transplantation: multicenter study in 4,767 recipients in Italy, 1970-2006. Transplant Proc 2009; 41: 1227-1230 [PMID: 19460525 DOI: 10.1016/j.transproceed.2009.03.009]
45. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, Grandaliano G. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: 1317-1323 [PMID: 15800227 DOI: 10.1056/ NEJMoa042831]
46. Jonas S, Rayes N, Neumann U, Neuhaus R, Bechstein WO, Guckelberger O, Tullius SG, Serke S, Neuhaus P. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997; 80: 1141-1150 [PMID: 9305716]
47. Sanchez EQ, Marubashi S, Jung G, Levy MF, Goldstein RM, Molmenti EP, Fasola CG, Gonwa TA, Jennings LW, Brooks BK, Klintmalm GB. De novo tumors after liver transplantation: a single-institution experience. Liver Transpl 2002; 8: 285-291 [PMID: 11910575 DOI: 10.1053/jlts.2002.29350]
48. Frezza EE, Fung JJ, van Thiel DH. Non-lymphoid cancer after liver transplantation. Hepatogastroenterology 1997; 44: 1172-1181 [PMID: 9261620]
49. Jiménez C, Manrique A, Marqués E, Ortega P, Loinaz C, Gómez R, Meneu JC, Abradelo M, Moreno A, López A, Moreno E. Incidence and risk factors for the development of lung tumors after liver transplantation. Transpl Int 2007; 20: 57-63 [PMID: 17181654 DOI: 10.1111/j.1432-2277.2006.00397.x]
50. Duvoux C, Delacroix I, Richardet JP, Roudot-Thoraval F, Métreau JM, Fagniez PL, Dhumeaux D, Cherqui D. Increased incidence of oropharyngeal squamous cell carcinomas after liver transplantation for alcoholic cirrhosis. Transplantation 1999; 67: 418-421 [PMID: 10030289]
51. Tallón Aguilar L, Barrera Pulido L, Bernal Bellido C, Pareja Ciuró F, Suárez Artacho G, Alamo Martínez JM, García González I, Gómez Bravo MA, Bernardos Rodríguez A. Causes and predisposing factors of de novo tumors in our series of liver transplant recipients. Transplant Proc 2009; 41: 2453-2454 [PMID: 19715949 DOI: 10.1016/j.transproceed.2009.05.012]
52. Jain A, DiMartini A, Kashyap R, Youk A, Rohal S, Fung J. Longterm follow-up after liver transplantation for alcoholic liver disease under tacrolimus. Transplantation 2000; 70: 1335-1342 [PMID: 11087149]
53. Bellamy CO, DiMartini AM, Ruppert K, Jain A, Dodson F, Torbenson M, Starzl TE, Fung JJ, Demetris AJ. Liver transplantation for alcoholic cirrhosis: long term follow-up and impact of disease recurrence. Transplantation 2001; 72: 619-626 [PMID: 11544420]
54. Schmilovitz-Weiss H, Mor E, Sulkes J, Bar-Nathan N, Shaharabani E, Melzer E, Tur-Kaspa R, Ben-Ari Z. De novo tumors after liver transplantation: a single-center experience. Transplant Proc 2003; 35: 665-666 [PMID: 12644086]
55. Castelli E, Hrelia P, Maffei F, Fimognari C, Foschi FG, Caputo F, Cantelli-Forti G, Stefanini GF, Gasbarrini G. Indicators of genetic damage in alcoholics: reversibility after alcohol abstinence. Hepatogastroenterology 1999; 46: 1664-1668 [PMID: 10430317]
56. Franceschi S, Talamini R, Barra S, Barón AE, Negri E, Bidoli E, Serraino D, La Vecchia C. Smoking and drinking in relation to cancers of the oral cavity, pharynx, larynx, and esophagus in northern Italy. Cancer Res 1990; 50: 6502-6507 [PMID: 2208109]
57. Adami J, Gäbel H, Lindelöf B, Ekström K, Rydh B, Glimelius B, Ekbom A, Adami HO, Granath F. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003; 89: 1221-1227 [PMID: 14520450 DOI: 10.1038/ sj.bjc.6601219]
58. Penn I. Cancers complicating organ transplantation. N Engl J Med 1990; 323: 1767-1769 [PMID: 2247108 DOI: 10.1056/ NEJM199012203232510]
59. Cogliano VJ, Baan R, Straif K, Grosse Y, Lauby-Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Wild CP. Preventable exposures associated with human cancers. J Natl Cancer Inst 2011; 103: 1827-1839 [PMID: 22158127 DOI: 10.1093/jnci/djr483]
60. Gaglio PJ, Gaglio PJ. Complications in patients with alcoholassociated liver disease who undergo liver transplantation. Clin Liver Dis 2012; 16: 865-875 [PMID: 23101987 DOI: 10.1016/ j.cld.2012.08.013]
61. Presser SJ, Schumacher G, Neuhaus R, Thuss-Patience P, Stieler J, Neuhaus P. De novo esophageal neoplasia after liver transplantation. Liver Transpl 2007; 13: 443-450 [PMID: 17318861 DOI: 10.1002/lt.21058]
62. Oezcelik A, Kaiser GM, Dechêne A, Treckmann JW, Sotiropoulos GC, Reinhardt R, Saner FH, Paul A. Progression to adenocarcinoma in Barrett's esophagus after liver transplantation. Transplantation 2011; 91: 1250-1253 [PMID: 21464795 DOI: 10.1097/TP.0b013e31821841a0]
63. Ilan Y, Shouval D, Galun E, Goldin E, Ligumsky M, Friedman G, Tur Kaspa R. Esophageal malignancy after liver transplantation in a patient with Barrett's esophagus. Scand J Gastroenterol 1996; 31: 415-416 [PMID: 8726313]
64. Trotter JF, Brazer SR. Rapid progression to high-grade dysplasia in Barrett's esophagus after liver transplantation. Liver Transpl Surg 1999; 5: 332-333 [PMID: 10388506 DOI: 10.1002/ lt.500050405]
65. Yao F, Ahuja J, Savides T, Behling C, Li S, Hart M. Rapid progression of gastroesophageal junction adenocarcinoma after liver transplantation. J Clin Gastroenterol 1997; 24: 54-55 [PMID: 9013353]
66. Safadi R, Ilan Y, Eid A, Galun E, Ashur Y, Goldin E, Papo O, Blachar A, Jurim O. Solid tumors after liver transplantation. Transplant Proc 1999; 31: 1894-1895 [PMID: 10371989]
67. Na S, Lee GH, Song JH, Ahn JY, Kim SO, Park SJ, Park SE, Kim MY, Lee J, Choi KS, Kim do H, Song HJ, Choi KD, Jung HY, Kim JH. Endoscopic resection of gastric neoplasm in solid-organ transplant recipients. Transplantation 2014; 97: 781-787 [PMID: 24406452 DOI: 10.1097/01.TP.0000438638.29214.f4]
68. Buell JF, Husted T, Hanaway MJ, Peddi VR, Trofe J, Gross TG, Beebe TM, First MR, Woodle ES. Incidental diagnosis of gastric cancer in transplant recipients improves patient survival. Surgery 2002; 132: 754-758; discussion 758-760 [PMID: 12407362]
69. Penn I. Posttransplantation de novo tumors in liver allograft recipients. Liver Transpl Surg 1996; 2: 52-59 [PMID: 9346628]
70. Vera A, Gunson BK, Ussatoff V, Nightingale P, Candinas D, Radley S, Mayer A, Buckels JA, McMaster P, Neuberger J, Mirza DF. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation 2003; 75: 1983-1988 [PMID: 12829898 DOI: 10.1097/01.TP.0000058744.34965.38]
71. Bleday R, Lee E, Jessurun J, Heine J, Wong WD. Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease. Dis Colon Rectum 1993; 36: 908-912 [PMID: 8404380]
72. Fabia R, Levy MF, Testa G, Obiekwe S, Goldstein RM, Husberg BS, Gonwa TA, Klintmalm GB. Colon carcinoma in patients undergoing liver transplantation. Am J Surg 1998; 176: 265-269 [PMID: 9776156]
73. Buell JF, Papaconstantinou HT, Skalow B, Hanaway MJ, Alloway RR, Woodle ES. De novo colorectal cancer: five-year survival is markedly lower in transplant recipients compared with the general population. Transplant Proc 2005; 37: 960-961 [PMID: 15848590 DOI: 10.1016/j.transproceed.2004.12.122]
74. Johnson EE, Leverson GE, Pirsch JD, Heise CP. A 30-year analysis of colorectal adenocarcinoma in transplant recipients and proposal for altered screening. J Gastrointest Surg 2007; 11: 272-279 [PMID: 17458597 DOI: 10.1007/s11605-007-0084-4]
75. Trevisani F, Garuti F, Cucchetti A, Lenzi B, Bernardi M. De novo hepatocellular carcinoma of liver allograft: a neglected issue. Cancer Lett 2015; 357: 47-54 [PMID: 25444925 DOI: 10.1016/ j.canlet.2014.11.032]
76. Adam R, Karam V, Delvart V, O'Grady J, Mirza D, Klempnauer J, Castaing D, Neuhaus P, Jamieson N, Salizzoni M, Pollard S, Lerut J, Paul A, Garcia-Valdecasas JC, Rodríguez FS, Burroughs A. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 2012; 57: 675-688 [PMID: 22609307 DOI: 10.1016/j.jhep.2012.04.015]
77. Angelico M, Cillo U, Fagiuoli S, Gasbarrini A, Gavrila C, Marianelli T, Costa AN, Nardi A, Strazzabosco M, Burra P, Agnes S, Baccarani U, Calise F, Colledan M, Cuomo O, De Carlis L, Donataccio M, Ettorre GM, Gerunda GE, Gridelli B, Lupo L, Mazzaferro V, Pinna A, Risaliti A, Salizzoni M, Tisone G, Valente U, Rossi G, Rossi M, Zamboni F. Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Dig Liver Dis 2011; 43: 155-164 [PMID: 21185796 DOI: 10.1016/ j.dld.2010.11.002]
78. Flemming P, Tillmann HL, Barg-Hock H, Kleeberger W, Manns MP, Klempnauer J, Kreipe HH. Donor origin of de novo hepatocellular carcinoma in hepatic allografts. Transplantation 2003; 76: 1625-1627 [PMID: 14702536 DOI: 10.1097/01. TP.0000086341.57778.D9]
79. Levitsky J, Faust TW, Cohen SM, Te HS. Group G streptococcal bacteremia and de novo hepatocellular carcinoma after liver transplantation. Liver Transpl 2002; 8: 572 [PMID: 12037793 DOI: 10.1002/lt.500080614]
80. Croitoru A, Schiano TD, Schwartz M, Roayaie S, Xu R, Suriawinata A, Fiel MI. De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci 2006; 51: 1780-1782 [PMID: 16967310 DOI: 10.1007/s10620-006-9333-8]
81. Sotiropoulos GC, Frilling A, Molmenti EP, Brokalaki EI, Beckebaum S, Omar OS, Broelsch CE, Malagó M. De novo hepatocellular carcinoma in recurrent liver cirrhosis after liver transplantation for benign hepatic disease: is a deceased donor retransplantation justified? Transplantation 2006; 82: 1112 [PMID: 17060864 DOI: 10.1097/01.tp.0000230283.84633.4a]
82. Kita Y, Klintmalm G, Kobayashi S, Yanaga K. Retransplantation for de novo hepatocellular carcinoma in a liver allograft with recurrent hepatitis B cirrhosis 14 years after primary liver transplantation. Dig Dis Sci 2007; 52: 3392-3393 [PMID: 17404871 DOI: 10.1007/s10620-006-9574-6]
83. Teng MW, Swann JB, Koebel CM, Schreiber RD, Smyth MJ. Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol 2008; 84: 988-993 [PMID: 18515327 DOI: 10.1189/ jlb.1107774]
84. Strauss DC, Thomas JM. Transmission of donor melanoma by organ transplantation. Lancet Oncol 2010; 11: 790-796 [PMID: 20451456 DOI: 10.1016/S1470-2045(10)70024-3]
85. Ison MG, Nalesnik MA. An update on donor-derived disease transmission in organ transplantation. Am J Transplant 2011; 11: 1123-1130 [PMID: 21443676 DOI: 10.1111/j.1600-6143.2011.03493.x]
86. Kauffman HM, McBride MA, Delmonico FL. First report of the United Network for Organ Sharing Transplant Tumor Registry: donors with a history of cancer. Transplantation 2000; 70: 1747-1751 [PMID: 11152107]
87. Kauffman HM, Cherikh WS, McBride MA, Cheng Y, Hanto DW. Deceased donors with a past history of malignancy: an organ procurement and transplantation network/united network for organ sharing update. Transplantation 2007; 84: 272-274 [PMID: 17667822 DOI: 10.1097/01.tp.0000267919.93425.fb]
88. Ison MG, Hager J, Blumberg E, Burdick J, Carney K, Cutler J, Dimaio JM, Hasz R, Kuehnert MJ, Ortiz-Rios E, Teperman L, Nalesnik M. Donor-derived disease transmission events in the United States: data reviewed by the OPTN/UNOS Disease Transmission Advisory Committee. Am J Transplant 2009; 9: 1929-1935 [PMID: 19538493 DOI: 10.1111/j.1600-6143.2009.02700.x]
89. Birkeland SA, Storm HH. Risk for tumor and other disease transmission by transplantation: a population-based study of unrecognized malignancies and other diseases in organ donors. Transplantation 2002; 74: 1409-1413 [PMID: 12451241 DOI: 10.1097/01.TP.0000034717.19606.B5]
90. Feng S, Buell JF, Chari RS, DiMaio JM, Hanto DW. Tumors and transplantation: The 2003 Third Annual ASTS State-of-the-Art Winter Symposium. Am J Transplant 2003; 3: 1481-1487 [PMID: 14629278]
91. Myron Kauffman H, McBride MA, Cherikh WS, Spain PC, Marks WH, Roza AM. Transplant tumor registry: donor related malignancies. Transplantation 2002; 74: 358-362 [PMID: 12177614]
92. Desai R, Neuberger J. Donor transmitted and de novo cancer after liver transplantation. World J Gastroenterol 2014; 20: 6170-6179 [PMID: 24876738 DOI: 10.3748/wjg.v20.i20.6170]
93. Buell JF, Trofe J, Sethuraman G, Hanaway MJ, Beebe TM, Gross TG, Alloway R, First MR, Woodle ES. Donors with central nervous system malignancies: are they truly safe? Transplantation 2003; 76: 340-343 [PMID: 12883189 DOI: 10.1097/01. TP.0000076094.64973.D8]
94. Watson CJ, Roberts R, Wright KA, Greenberg DC, Rous BA, Brown CH, Counter C, Collett D, Bradley JA. How safe is it to transplant organs from deceased donors with primary intracranial malignancy? An analysis of UK Registry data. Am J Transplant 2010; 10: 1437-1444 [PMID: 20486904 DOI: 10.1111/ j.1600-6143.2010.03130.x]
95. Abramowicz D, Cochat P, Claas FH, Heemann U, Pascual J, Dudley C, Harden P, Hourmant M, Maggiore U, Salvadori M, Spasovski G, Squifflet JP, Steiger J, Torres A, Viklicky O, Zeier M, Vanholder R, Van Biesen W, Nagler E. European Renal Best Practice Guideline on kidney donor and recipient evaluation and perioperative care. Nephrol Dial Transplant 2014; Epub ahead of print [PMID: 25007790 DOI: 10.1093/ndt/gfu216]
96. Buell JF, Beebe TM, Trofe J, Gross TG, Alloway RR, Hanaway MJ, Woodle ES. Donor transmitted malignancies. Ann Transplant 2004; 9: 53-56 [PMID: 15478892]
97. Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs 2007; 67: 1167-1198 [PMID: 17521218]
98. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 59-67 [PMID: 17617273 DOI: 10.1016/S0140-6736(07)61050-2]
99. Soulillou JP, Giral M. Controlling the incidence of infection and malignancy by modifying immunosuppression. Transplantation 2001; 72: S89-S93 [PMID: 11833147]
100. Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B, Soulillou JP. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623-628 [PMID: 9500317 DOI: 10.1016/S0140-6736(97)08496-1]
101. Tanner JE, Alfieri C. The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transpl Infect Dis 2001; 3: 60-69 [PMID: 11395971]
102. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, Shimbo T, Suthanthiran M. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530-534 [PMID: 10028970 DOI: 10.1038/17401]
103. Yarosh DB, Pena AV, Nay SL, Canning MT, Brown DA. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol 2005; 125: 1020-1025 [PMID: 16297204 DOI: 10.1111/ j.0022-202X.2005.23858.x]
104. Herman M, Weinstein T, Korzets A, Chagnac A, Ori Y, Zevin D, Malachi T, Gafter U. Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. J Lab Clin Med 2001; 137: 14-20 [PMID: 11150019 DOI: 10.1067/ mlc.2001.111469]
105. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-135 [PMID: 11821896 DOI: 10.1038/nm0202-128]
106. Maluccio M, Sharma V, Lagman M, Vyas S, Yang H, Li B, Suthanthiran M. Tacrolimus enhances transforming growth factorbeta1 expression and promotes tumor progression. Transplantation 2003; 76: 597-602 [PMID: 12923450 DOI: 10.1097/01. TP.0000081399.75231.3B]
107. Suthanthiran M, Hojo M, Maluccio M, Boffa DJ, Luan FL. Posttransplantation malignancy: a cell autonomous mechanism with implications for therapy. Trans Am Clin Climatol Assoc 2009; 120: 369-388 [PMID: 19768190]
108. Walsh SB, Xu J, Xu H, Kurundkar AR, Maheshwari A, Grizzle WE, Timares L, Huang CC, Kopelovich L, Elmets CA, Athar M. Cyclosporine a mediates pathogenesis of aggressive cutaneous squamous cell carcinoma by augmenting epithelial-mesenchymal transition: role of TGFβ signaling pathway. Mol Carcinog 2011; 50: 516-527 [PMID: 21308804 DOI: 10.1002/mc.20744]
109. Tjon AS, Sint Nicolaas J, Kwekkeboom J, de Man RA, Kazemier G, Tilanus HW, Hansen BE, van der Laan LJ, Tha-In T, Metselaar HJ. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. Liver Transpl 2010; 16: 837-846 [PMID: 20583092 DOI: 10.1002/lt.22064]
110. Rodríguez-Perálvarez M, Germani G, Papastergiou V, Tsochatzis E, Thalassinos E, Luong TV, Rolando N, Dhillon AP, Patch D, O' Beirne J, Thorburn D, Burroughs AK. Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome. J Hepatol 2013; 58: 262-270 [PMID: 23023010 DOI: 10.1016/j.jhep.2012.09.019]
111. Ezbay LA, Smidt K, Mortensen DM, Carstens J, Jørgensen KA, Rungby J. Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells. Br J Pharmacol 2011; 162: 136-146 [PMID: 20825407 DOI: 10.1111/ j.1476-5381.2010.01018.x]
112. Chakkera HA, Mandarino LJ. Calcineurin inhibition and new-onset diabetes mellitus after transplantation. Transplantation 2013; 95: 647-652 [PMID: 23076551 DOI: 10.1097/TP.0b013e31826e592e]
113. Soleimanpour SA, Crutchlow MF, Ferrari AM, Raum JC, Groff DN, Rankin MM, Liu C, De León DD, Naji A, Kushner JA, Stoffers DA. Calcineurin signaling regulates human islet {beta}-cell survival. J Biol Chem 2010; 285: 40050-40059 [PMID: 20943662 DOI: 10.1074/jbc.M110.154955]
114. Navasa M, Bustamante J, Marroni C, González E, Andreu H, Esmatjes E, García-Valdecasas JC, Grande L, Cirera I, Rimola A, Rodés J. Diabetes mellitus after liver transplantation: prevalence and predictive factors. J Hepatol 1996; 25: 64-71 [PMID: 8836903]
115. Trail KC, McCashland TM, Larsen JL, Heffron TG, Stratta RJ, Langnas AN, Fox IJ, Zetterman RK, Donovan JP, Sorrell MF, Pillen TJ, Ruby EI, Shaw BW. Morbidity in patients with posttransplant diabetes mellitus following orthotopic liver transplantation. Liver Transpl Surg 1996; 2: 276-283 [PMID: 9346661]
116. Levy G, Villamil F, Samuel D, Sanjuan F, Grazi GL, Wu Y, Marotta P, Boillot O, Muehlbacher F, Klintmalm G. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 2004; 77: 1632-1638 [PMID: 15201658]
117. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4: 369-380 [PMID: 16527702 DOI: 10.1016/j.cgh.2005.12.007]
118. Penn I. The changing pattern of posttransplant malignancies. Transplant Proc 1991; 23: 1101-1103 [PMID: 1899153]
119. Howard TK, Klintmalm GB, Stone MJ, Cofer JB, Husberg BS, Goldstein RM, Gonwa TA. Lymphoproliferative disorder masquerading as rejection in liver transplant recipients--an early aggressive tumor with atypical presentation. Transplantation 1992; 53: 1145-1147 [PMID: 1316652]
120. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL, Dizikes GJ, Pifarre R, Fisher RI. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323: 1723-1728 [PMID: 2100991 DOI: 10.1056/NEJM199012203232502]
121. Penninga L, Wettergren A, Wilson CH, Chan AW, Steinbrüchel DA, Gluud C. Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients. Cochrane Database Syst Rev 2014; 6: CD010253 [PMID: 24901467 DOI: 10.1002/14651858.CD010253.pub2]
122. Neuhaus P, Klupp J, Langrehr JM. mTOR inhibitors: an overview. Liver Transpl 2001; 7: 473-484 [PMID: 11443573 DOI: 10.1053/ jlts.2001.24645]
123. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004; 18: 446-449 [PMID: 15233824 DOI: 10.1111/j.1399-0012.2004.00188.x]
124. Klintmalm GB, Saab S, Hong JC, Nashan B. The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy. Clin Transplant 2014; 28: 635-648 [PMID: 24628264 DOI: 10.1111/ctr.12357]
125. Ewald F, Grabinski N, Grottke A, Windhorst S, Nörz D, Carstensen L, Staufer K, Hofmann BT, Diehl F, David K, Schumacher U, Nashan B, Jücker M. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. Int J Cancer 2013; 133: 2065-2076 [PMID: 23588885 DOI: 10.1002/ijc.28214]
126. Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B, Jücker M. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer 2012; 11: 85 [PMID: 23167739 DOI: 10.1186/1476-4598-11-85]
127. Rodríguez-Perálvarez M, De la Mata M, Burroughs AK. Liver transplantation: immunosuppression and oncology. Curr Opin Organ Transplant 2014; 19: 253-260 [PMID: 24685671 DOI: 10.1097/MOT.0000000000000069]
128. Finkenstedt A, Graziadei IW, Oberaigner W, Hilbe W, Nachbaur K, Mark W, Margreiter R, Vogel W. Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients. Am J Transplant 2009; 9: 2355-2361 [PMID: 19663894 DOI: 10.1111/j.1600-6143.2009.02766.x]
129. Herrero JI, Alegre F, Quiroga J, Pardo F, Iñarrairaegui M, Sangro B, Rotellar F, Montiel C, Prieto J. Usefulness of a program of neoplasia surveillance in liver transplantation. A preliminary report. Clin Transplant 2009; 23: 532-536 [PMID: 19681977 DOI: 10.1111/j.1399-0012.2008.00927.x]
130. Chak E, Saab S. Risk factors and incidence of de novo malignancy in liver transplant recipients: a systematic review. Liver Int 2010; 30: 1247-1258 [PMID: 20602682 DOI: 10.1111/ j.1478-3231.2010.02303.x]
131. U.S. Preventive Services Task Force1. Screening for skin cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150: 188-193 [PMID: 19189908]
132. Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM, Gaston RS, Roth D, Scandling JD, Singer GG. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000; 11 Suppl 15: S1-86 [PMID: 11044969]
133. Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G, Huang H, Lee SJ, Munsell M, Plevritis SK, Ravdin P, Schechter CB, Sigal B, Stoto MA, Stout NK, van Ravesteyn NT, Venier J, Zelen M, Feuer EJ. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med 2009; 151: 738-747 [PMID: 19920274 DOI: 10.7326/0003-4819-151-10-200911170-00010]
134. U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149: 627-637 [PMID: 18838716]
135. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365: 395-409 [PMID: 21714641 DOI: 10.1056/NEJMoa1102873]
136. Geissler EK, Schlitt HJ, Thomas G. mTOR, cancer and transplantation. Am J Transplant 2008; 8: 2212-2218 [PMID: 18785960 DOI: 10.1111/j.1600-6143.2008.02391.x]
137. Koehl GE, Andrassy J, Guba M, Richter S, Kroemer A, Scherer MN, Steinbauer M, Graeb C, Schlitt HJ, Jauch KW, Geissler EK. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004; 77: 1319-1326 [PMID: 15167584]
138. Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002; 73: 1565-1572 [PMID: 12042641]
139. Kahan BD, Camardo JS. Rapamycin: clinical results and future opportunities. Transplantation 2001; 72: 1181-1193 [PMID: 11602840]
140. Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, Claesson K, Stallone G, Russ G, Rostaing L, Kreis H, Burke JT, Brault Y, Scarola JA, Neylan JF. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17: 581-589 [PMID: 16434506 DOI: 10.1681/ASN.2005090993]
141. Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233-242 [PMID: 19155978 DOI: 10.1097/TP.0b013e3181927a41]
142. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80: 883-889 [PMID: 16249734]
143. Kahan BD, Yakupoglu YK, Schoenberg L, Knight RJ, Katz SM, Lai D, Van Buren CT. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005; 80: 749-758 [PMID: 16210961]
144. Alberú J, Pascoe MD, Campistol JM, Schena FP, Rial Mdel C, Polinsky M, Neylan JF, Korth-Bradley J, Goldberg-Alberts R, Maller ES. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitorfree immunotherapy: 24-month results from the CONVERT trial. Transplantation 2011; 92: 303-310 [PMID: 21792049 DOI: 10.1097/TP.0b013e3182247ae2]
145. Zuckermann A, Manito N, Epailly E, Fiane A, Bara C, Delgado JF, Lehmkuhl H, Ross H, Eisen H, Chapman J, Valantine H. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Heart Lung Transplant 2008; 27: 141-149 [PMID: 18267219 DOI: 10.1016/ j.healun.2007.08.014]
146. Gomez-Camarero J, Salcedo M, Rincon D, Lo Iacono O, Ripoll C, Hernando A, Sanz C, Clemente G, Bañares R. Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. Transplantation 2007; 84: 786-791 [PMID: 17893613 DOI: 10.1097/01.tp.0000280549.93403.dd]
147. Thimonier E, Guillaud O, Walter T, Decullier E, Vallin M, Boillot O, Dumortier J. Conversion to everolimus dramatically improves the prognosis of de novo malignancies after liver transplantation for alcoholic liver disease. Clin Transplant 2014; 28: 1339-1348 [PMID: 25081431 DOI: 10.1111/ctr.12430]
148. Benten D, Sterneck M, Panse J, Rogiers X, Lohse AW. Low recurrence of preexisting extrahepatic malignancies after liver transplantation. Liver Transpl 2008; 14: 789-798 [PMID: 18412260 DOI: 10.1002/lt.21434]
149. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.10. Pregnancy in renal transplant recipients. Nephrol Dial Transplant 2002; 17 Suppl 4: 50-55 [PMID: 12091650]
150. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699 [PMID: 8594428 DOI: 10.1056/NEJM199603143341104]
151. Kasiske BL, Cangro CB, Hariharan S, Hricik DE, Kerman RH, Roth D, Rush DN, Vazquez MA, Weir MR. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant 2001; 1 Suppl 2: 3-95 [PMID: 12108435]
152. Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation 1993; 55: 742-747 [PMID: 8475546]
153. Castroagudín JF, Molina E, Bustamante M, Tomé S, Otero E, Martínez J, Segade FR, Conde R, Varo E. Orthotopic liver transplantation for hepatocellular carcinoma: a thirteen-year single-center experience. Transplant Proc 2008; 40: 2975-2977 [PMID: 19010164 DOI: 10.1016/j.transproceed.2008.09.006]
154. Chinnakotla S, Davis GL, Vasani S, Kim P, Tomiyama K, Sanchez E, Onaca N, Goldstein R, Levy M, Klintmalm GB. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 2009; 15: 1834-1842 [PMID: 19938137 DOI: 10.1002/lt.21953]
155. DuBay D, Sandroussi C, Sandhu L, Cleary S, Guba M, Cattral MS, McGilvray I, Ghanekar A, Selzner M, Greig PD, Grant DR. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg 2011; 253: 166-172 [PMID: 21294289]
156. Vivarelli M, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, Lauro A, Grazi GL, Pinna AD. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 2008; 248: 857-862 [PMID: 18948815 DOI: 10.1097/SLA.0b013e3181896278]
157. Sotiropoulos GC, Molmenti EP, Lösch C, Beckebaum S, Broelsch CE, Lang H. Meta-analysis of tumor recurrence after liver transplantation for hepatocellular carcinoma based on 1,198 cases. Eur J Med Res 2007; 12: 527-534 [PMID: 18024261]
158. Kornberg A, Küpper B, Tannapfel A, Katenkamp K, Thrum K, Habrecht O, Wilberg J. Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables. Eur J Surg Oncol 2010; 36: 275-280 [PMID: 19857941 DOI: 10.1016/j.ejso.2009.10.001]
159. Vivarelli M, Dazzi A, Zanello M, Cucchetti A, Cescon M, Ravaioli M, Del Gaudio M, Lauro A, Grazi GL, Pinna AD. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. Transplantation 2010; 89: 227-231 [PMID: 20098287 DOI: 10.1097/TP.0b013e3181c3c540]
160. Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC, Pieri G, García-Caparrós C, O'Beirne J, Poyato-González A, Ferrín-Sánchez G, Montero-Álvarez JL, Patch D, Thorburn D, Briceo J, De la Mata M, Burroughs AK. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol 2013; 59: 1193-1199 [PMID: 23867318 DOI: 10.1016/j.jhep.2013.07.012]
161. Chapman TM, Perry CM. Everolimus. Drugs 2004; 64: 861-872; discussion 873-874 [PMID: 15059040]
162. Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010; 51: 1237-1243 [PMID: 20187107 DOI: 10.1002/ hep.23437]
163. Ashworth RE, Wu J. Mammalian target of rapamycin inhibition in hepatocellular carcinoma. World J Hepatol 2014; 6: 776-782 [PMID: 25429315 DOI: 10.4254/wjh.v6.i11.776]
164. Zhou L, Huang Y, Li J, Wang Z. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol 2010; 27: 255-261 [PMID: 19301157 DOI: 10.1007/ s12032-009-9201-4]
165. Liang W, Wang D, Ling X, Kao AA, Kong Y, Shang Y, Guo Z, He X. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl 2012; 18: 62-69 [PMID: 21964956 DOI: 10.1002/lt.22441]
166. Menon KV, Hakeem AR, Heaton ND. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther 2013; 37: 411-419 [PMID: 23278125 DOI: 10.1111/apt.12185]
167. Cholongitas E, Mamou C, Rodríguez-Castro KI, Burra P. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int 2014; 27: 1039-1049 [PMID: 24943720 DOI: 10.1111/tri.12372]
168. Cholongitas E, Burra P. Reply to: Time to resize the role of everolimus as treatment of hepatocellular carcinoma recurrence after liver transplant. Transpl Int 2015; 28: 503-504 [PMID: 25440876 DOI: 10.1111/tri.12496]
169. Pruthi J, Medkiff KA, Esrason KT, Donovan JA, Yoshida EM, Erb SR, Steinbrecher UP, Fong TL. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 2001; 7: 811-815 [PMID: 11552217 DOI: 10.1053/ jlts.2001.27084]
170. Schoening WN, Buescher N, Rademacher S, Andreou A, Kuehn S, Neuhaus R, Guckelberger O, Puhl G, Seehofer D, Neuhaus P. Twenty-year longitudinal follow-up after orthotopic liver transplantation: a single-center experience of 313 consecutive cases. Am J Transplant 2013; 13: 2384-2394 [PMID: 23915357 DOI: 10.1111/ajt.12384]
171. Zhou J, Wang Z, Wu ZQ, Qiu SJ, Yu Y, Huang XW, Tang ZY, Fan J. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. Transplant Proc 2008; 40: 3548-3553 [PMID: 19100435 DOI: 10.1016/j.transproceed.2008.03.165]
172. Schnitzbauer AA, Zuelke C, Graeb C, Rochon J, Bilbao I, Burra P, de Jong KP, Duvoux C, Kneteman NM, Adam R, Bechstein WO, Becker T, Beckebaum S, Chazouillères O, Cillo U, Colledan M, Fändrich F, Gugenheim J, Hauss JP, Heise M, Hidalgo E, Jamieson N, Königsrainer A, Lamby PE, Lerut JP, Mäkisalo H, Margreiter R, Mazzaferro V, Mutzbauer I, Otto G, Pageaux GP, Pinna AD, Pirenne J, Rizell M, Rossi G, Rostaing L, Roy A, Turrion VS, Schmidt J, Troisi RI, van Hoek B, Valente U, Wolf P, Wolters H, Mirza DF, Scholz T, Steininger R, Soderdahl G, Strasser SI, Jauch KW, Neuhaus P, Schlitt HJ, Geissler EK. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer 2010; 10: 190 [PMID: 20459775 DOI: 10.1186/1471 -2407-10-190]
173. Gomez-Martin C, Bustamante J, Castroagudin JF, Salcedo M, Garralda E, Testillano M, Herrero I, Matilla A, Sangro B. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl 2012; 18: 45-52 [PMID: 21932373 DOI: 10.1002/lt.22434]
174. McCaughan GW, Vajdic CM. De novo malignant disease after liver transplantation? Risk and surveillance strategies. Liver Transpl 2013; 19 Suppl 2: S62-S67 [PMID: 24019077 DOI: 10.1002/lt.23738]
175. Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant 2010; 10: 1889-1896 [PMID: 20659094 DOI: 10.1111/j.1600-6143.2010.03181.x]
176. Aberg F, Pukkala E, Höckerstedt K, Sankila R, Isoniemi H. Risk of malignant neoplasms after liver transplantation: a populationbased study. Liver Transpl 2008; 14: 1428-1436 [PMID: 18825704 DOI: 10.1002/lt.21475]
177. Engels EA, Pfeiffer RM, Fraumeni JF, Kasiske BL, Israni AK, Snyder JJ, Wolfe RA, Goodrich NP, Bayakly AR, Clarke CA, Copeland G, Finch JL, Fleissner ML, Goodman MT, Kahn A, Koch L, Lynch CF, Madeleine MM, Pawlish K, Rao C, Williams MA, Castenson D, Curry M, Parsons R, Fant G, Lin M. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011; 306: 1891-1901 [PMID: 22045767 DOI: 10.1001/jama.2011.1592]
178. Baccarani U, Piselli P, Serraino D, Adani GL, Lorenzin D, Gambato M, Buda A, Zanus G, Vitale A, De Paoli A, Cimaglia C, Bresadola V, Toniutto P, Risaliti A, Cillo U, Bresadola F, Burra P. Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries. Dig Liver Dis 2010; 42: 55-60 [PMID: 19497797 DOI: 10.1016/j.dld.2009.04.017]
179. Antinucci F, Anders M, Orozco F, Mella J, Cobos M, McCormack L, Mastai R. [De novo malignant tumors following liver transplantation. A single-center experience in Argentina]. Medicina (B Aires) 2015; 75: 18-22 [PMID: 25637895]
180. Yao FY, Gautam M, Palese C, Rebres R, Terrault N, Roberts JP, Peters MG. De novo malignancies following liver transplantation: a casecontrol study with long-term follow-up. Clin Transplant 2006; 20: 617-623 [PMID: 16968488 DOI: 10.1111/j.1399-0012.2006.00527.x]
181. Jiménez C, Rodríguez D, Marqués E, Loinaz C, Alonso O, Hernández-Vallejo G, Marín L, Rodríguez F, García I, Moreno E. De novo tumors after orthotopic liver transplantation. Transplant Proc 2002; 34: 297-298 [PMID: 11959293]
182. Sint Nicolaas J, de Jonge V, Steyerberg EW, Kuipers EJ, van Leerdam ME, Veldhuyzen-van Zanten SJ. Risk of colorectal carcinoma in post-liver transplant patients: a systematic review and meta-analysis. Am J Transplant 2010; 10: 868-876 [PMID: 20420641 DOI: 10.1111/j.1600-6143.2010.03049.x]
183. Jiménez-Romero C, Manrique Municio A, Marqués Medina E, Colina F, Ortega Domene P, Gómez Sanz R, Meneu DiazJC, Abradelo de Usera M, Moreno Elola A, Moreno Gonzalez E. Incidence of de novo nonmelanoma skin tumors after liver transplantation for alcoholic and nonalcoholic liver diseases. Transplant Proc 2006; 38: 2505-2507 [PMID: 17097982 DOI: 10.1016/j.transproceed.2006.08.065]
184. Jain A, Nalesnik M, Reyes J, Pokharna R, Mazariegos G, Green M, Eghtesad B, Marsh W, Cacciarelli T, Fontes P, Abu-Elmagd K, Sindhi R, Demetris J, Fung J. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg 2002; 236: 429-436; discussion 436-437 [PMID: 12368671 DOI: 10.1097/01.SLA.0000033429.89424.F8]